Results 111 to 120 of about 14,491 (226)

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review

Discover Oncology
Anaplastic lymphoma kinase (ALK) gene fusion is a classic driver mutation in non-small cell lung cancer (NSCLC); however, ALK double-fusion variants in NSCLC have rarely been reported.
Pei Li, Xiao Ju, Guangjian Yang
semanticscholar   +1 more source

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. [PDF]

, 2019
PurposeDiarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.MethodsThis paper reviews data on the ...
Bosserman, Linda, Bryce, Richard, Di Palma, Jack A, Moran, Susan, Olek, Elizabeth, Rugo, Hope S, Tripathy, Debu   +6 more
core  

Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma.

Biomedical chromotography
Small molecule inhibitors (SMIs) are increasingly being used in the treatment of non-small cell lung cancer. To support pharmacokinetic research and clinical treatment monitoring, our aim was to develop and validate an ultra-performance liquid ...
Esther M Hollander, Nachel M C Zimmerman, B. Piet, M. M. van den Heuvel, D.M. Burger, Lindsey H M Te Brake, R. ter Heine   +6 more
semanticscholar   +1 more source

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

Lung Cancer: Targets and Therapy, 2023
Alexandria TM Lee,1 Saihong Ignatius Ou1,2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Saihong Ignatius Ou, University of ...
Lee AT, Ou SI
doaj  

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib

Journal of clinical laboratory analysis (Print)
Alectinib is a second‐generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK‐mutated non‐small‐cell lung cancer. Recently, the association between alectinib and red cell morphological abnormalities has been reported in a few case series.
Ting Hon Stanford Li, Yin Kwan Jeannie Chik, Ka Yan Ng, Wai Shan Wong   +3 more
semanticscholar   +1 more source

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China

Frontiers in Public Health
Background Iruplinalkib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with efficacy in patients with ALK-positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC), which is independently developed
Zhanjing Dai, Jiayi Xu, Feng Chang, Wanxin Zhou, Ting Ren, Jiaxin Qiu, Yun Lu, Yuqiong Lu   +7 more
semanticscholar   +1 more source

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib

JTO Clinical and Research Reports
Introduction: Central nervous system (CNS) metastases remain a common challenge in patients with ALK-positive NSCLC. We previously reported reinduction of CNS responses using dose-intensified alectinib in two patients with CNS progression on standard ...
Justin M. Cheung, MD, Jiyoon Kang, DO, Beow Y. Yeap, ScD, Jennifer L. Peterson, BS, Andrew Do, BS, Justin F. Gainor, MD, Subba R. Digumarthy, MD, Jessica J. Lin, MD   +7 more
doaj   +1 more source

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]

, 2019
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre, Klibanov, Olga, Olin, Jacqueline L, Spooner, Linda M   +3 more
core   +1 more source

Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory

Translational Lung Cancer Research
Background Alectinib, a next-generation anaplastic lymphoma kinase tyrosine kinase inhibitor (ALK-TKI), has demonstrated noteworthy efficacy in the treatment of non-small cell lung cancer (NSCLC).
Yimeng Li, Zhanpeng Hao, Yuyan Ma, Kaidiriye Setiwalidi, Yingming Zhang, Yujia Zhao, Xiao Fu, Xuan Liang, Z. Ruan, T. Tian, Yu Yao   +10 more
semanticscholar   +1 more source

Expression and amplification of HER2 and molecular markers of signal activation in the advanced or metastatic lung carcinoma [PDF]

, 2018
Die Arbeit beleuchtet die Bedeutung des Signalmoleküls HER2 im Rahmen der intrazellulären Signalweiterleitung sowie seine Bedeutung als prognostischer bzw. prädiktiver Marker im fortgeschrittenen bzw.
Huber, Ulrich Cyril
core